EGFR and lung carcinoma: DLC3 knockdown prevented EGFR degradation and enhanced Akt activation by trapping the receptor in EEA1-positive endosomes [41], making it tempting to speculate that reduced DLC3 expression might also confer EGFR-TKI resistance as described for lung cancers overexpressing RhoB [162].